Antonio Cano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1459276/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-use of information and communication technology as a predictor of frailty in postmenopausal midlife and older women. Maturitas, 2022, 156, 60-64.	1.0	2
2	Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 2022, 23, 1742.	1.8	0
3	It Is Premature to Use Postmortem Sperm for Reproductive Purposes: a Data-Driven Opinion. Reproductive Sciences, 2022, 29, 3387-3393.	1.1	1
4	Identification of Altered Evoked and Non-Evoked Responses in a Heterologous Mouse Model of Endometriosis-Associated Pain. Biomedicines, 2022, 10, 501.	1.4	4
5	Body weight and fat mass across the menopausal transition: hormonal modulators. Gynecological Endocrinology, 2022, 38, 99-104.	0.7	10
6	Nuts and Metabolic Syndrome: Reducing the Burden of Metabolic Syndrome in Menopause. Nutrients, 2022, 14, 1677.	1.7	3
7	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	2.7	83
8	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. Maturitas, 2021, 143, 223-230.	1.0	27
9	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. Climacteric, 2021, 24, 109-119.	1.1	22
10	Bazedoxifene increases the proliferation of human arterial endothelial cells but does not affect the expression of cyclins A, B, and D1 and of p27Kip1. Gynecological Endocrinology, 2021, 37, 269-272.	0.7	1
11	Go for it! Exercising makes you happy and strong Translational Medicine @ UniSa, 2021, 23, 92-105.	0.8	2
12	A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines, 2021, 9, 269.	1.4	9
13	Ovarian steroids and cancer: news on the breast, questions on the reproductive tract. Gynecological Endocrinology, 2021, 37, 383-384.	0.7	0
14	Positive association of high-density lipoprotein cholesterol with lumbar and femoral neck bone mineral density in postmenopausal women. Maturitas, 2021, 147, 41-46.	1.0	23
15	Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. ESMO Open, 2021, 6, 100148.	2.0	4
16	Variants translating reduced expression of the beta estrogen receptor gene were associated with increased carotid intima media thickness. Medicine (United States), 2021, 100, e26216.	0.4	0
17	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, 148, 55-61.	1.0	35
18	Female Genital Mutilation Consequences and Healthcare Received among Migrant Women: A Phenomenological Qualitative Study. International Journal of Environmental Research and Public Health, 2021, 18, 7195.	1.2	6

#	Article	IF	CITATIONS
19	The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview. Advances in Clinical and Experimental Medicine, 2021, 30, 879-883.	0.6	2
20	Serum microRNAs in osteoporotic fracture and osteoarthritis: a genetic and functional study. Scientific Reports, 2021, 11, 19372.	1.6	13
21	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. Maturitas, 2021, 151, 55-62.	1.0	28
22	Randomized Controlled Trial for Promotion of Healthy Eating in Older Adults by Increasing Consumption of Plant-Based Foods: Effect on Inflammatory Biomarkers. Nutrients, 2021, 13, 3753.	1.7	5
23	Public health and clinical approach to proactive management of frailty in multidimensional arena. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2021, 33, 543-554.	0.5	6
24	Polymorphisms in Genes Involved in Osteoblast Differentiation and Function Are Associated with Anthropometric Phenotypes in Spanish Women. Genes, 2021, 12, 2012.	1.0	0
25	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas, 2020, 131, 91-101.	1.0	37
26	The Mediterranean diet: A historical perspective on food for health. Maturitas, 2020, 132, 65-69.	1.0	68
27	A predictive model for women's assisted fecundity before starting the first IVF/ICSI treatment cycle. Journal of Assisted Reproduction and Genetics, 2020, 37, 171-180.	1.2	8
28	Differential expression of receptor activator of nuclear factor kappa B in healthy endometrium, ovarian endometrioma, and endometrioid ovarianÂcancer. American Journal of Obstetrics and Gynecology, 2020, 222, 279-281.	0.7	4
29	Cumulative probabilities of live birth across multiple complete IVF/ICSI cycles: a call for attention. Journal of Assisted Reproduction and Genetics, 2020, 37, 141-148.	1.2	4
30	Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety. Maturitas, 2020, 141, 85-86.	1.0	3
31	Diet to Reduce the Metabolic Syndrome Associated with Menopause. The Logic for Olive Oil. Nutrients, 2020, 12, 3184.	1.7	9
32	Comparative transcriptome analysis identifies CARM1 and DNMT3A as genes associated with osteoporosis. Scientific Reports, 2020, 10, 16298.	1.6	11
33	The Mediterranean diet and menopausal health: An EMAS position statement. Maturitas, 2020, 139, 90-97.	1.0	39
34	Response to "Should estrogen be used in the co-treatment of COVID-19 patients?― Maturitas, 2020, 140, 81-82.	1.0	1
35	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 2020, 80, 1537-1552.	4.9	40
36	The thromboembolic risk in covid-19 women under hormonal treatment group. Maturitas, 2020, 138, 78-79.	1.0	5

#	Article	IF	CITATIONS
37	Polymorphisms in genes involved in T-cell co-stimulation are associated with blood pressure in women. Gene, 2020, 754, 144838.	1.0	3
38	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas, 2020, 135, 82-88.	1.0	51
39	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. Osteoporosis International, 2020, 31, 2271-2286.	1.3	76
40	Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysis. Journal of Assisted Reproduction and Genetics, 2020, 37, 1203-1212.	1.2	20
41	Predictors of live birth in women with a history of biochemical pregnancies after assisted reproduction treatment. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 248, 198-203.	0.5	2
42	Mediterranean diet and health: A systematic review of epidemiological studies and intervention trials. Maturitas, 2020, 136, 25-37.	1.0	81
43	Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de GinecologÃa y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas, 2020, 137, 57-62.	1.0	43
44	Association of a single nucleotide polymorphism of RANK gene with blood pressure in Spanish women. Medicine (United States), 2020, 99, e22436.	0.4	1
45	Can Integrated Care Help in Meeting the Challenges Posed on Our Health Care Systems by COVID-19? Some Preliminary Lessons Learned from the European VIGOUR Project. International Journal of Integrated Care, 2020, 20, 4.	0.1	18
46	Management of Osteoporosis in Postmenopausal Women. , 2019, , 367-385.		0
47	Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines. BMC Medicine, 2019, 17, 193.	2.3	65
48	Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clinical Therapeutics, 2019, 41, 1576-1588.	1.1	33
49	Women's morbid conditions are associated with decreased odds of live birth in the first IVF/ICSI treatment: a retrospective single-center study. Journal of Assisted Reproduction and Genetics, 2019, 36, 697-708.	1.2	8
50	Menopause: Women should not suffer in silence. Maturitas, 2019, 124, 91-92.	1.0	4
51	On the use and abuse of register studies: The case of menopausal hormone therapy. Maturitas, 2019, 123, 91-92.	1.0	3
52	EMAS position statement: Predictors of premature and early natural menopause. Maturitas, 2019, 123, 82-88.	1.0	80
53	Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis. Journal of Visualized Experiments, 2019, , .	0.2	6
54	The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. Translational Medicine @ UniSa, 2019, 19, 66-81.	0.8	11

#	Article	IF	CITATIONS
55	Hormonal contraceptives and breast cancer: Clinical data. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 212-216.	0.5	11
56	The action of estrogens and progestogens in the young female breast. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 204-207.	0.5	12
57	Current management of pelvic organ prolapse in aging women: EMAS clinical guide. Maturitas, 2018, 110, 118-123.	1.0	21
58	Understanding frailty: a qualitative study of European healthcare policy-makers' approaches to frailty screening and management. BMJ Open, 2018, 8, e018653.	0.8	57
59	Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 140-232.	1.7	329
60	One small step in frailty research, a giant leap in evidence based practice. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1-3.	1.7	5
61	Perceptions and experiences of frailty interventions: quantitative and qualitative results from a survey of partners within the European Innovation Partnership on Active and Healthy Ageing (EIP-AHA). Ageing and Society, 2018, 38, 1843-1867.	1.2	11
62	Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas, 2018, 107, 7-12.	1.0	88
63	Comments on the USPSTF draft recommendation statement on menopausal hormone therapy: Primary prevention of chronic conditions. Maturitas, 2018, 107, A1-A2.	1.0	5
64	Frailty as the Future Core Business of Public Health: Report of the Activities of the A3 Action Group of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). International Journal of Environmental Research and Public Health, 2018, 15, 2843.	1.2	36
65	PoliFIT-INFOcus: A pilot study exploring how to promote physical activity in older people. European Journal of Internal Medicine, 2018, 57, e41-e42.	1.0	1
66	Understanding frailty: meanings and beliefs about screening and prevention across key stakeholder groups in Europe. Ageing and Society, 2018, 38, 1223-1252.	1.2	36
67	Knowledge, attitudes and practices of primary healthcare professionals to female genital mutilation in Valencia, Spain: are we ready for this challenge?. BMC Health Services Research, 2018, 18, 579.	0.9	19
68	Tackling frailty and functional decline: Background of the action group A3 of the European innovation partnership for active and healthy ageing. Maturitas, 2018, 115, 69-73.	1.0	20
69	Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. Maturitas, 2018, 116, 83-88.	1.0	4
70	Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level. International Journal of Molecular Sciences, 2018, 19, 1848.	1.8	5
71	Menopause and diabetes: EMAS clinical guide. Maturitas, 2018, 117, 6-10.	1.0	91
72	A realist review to understand the efficacy and outcomes of interventions designed to minimise, reverse or prevent the progression of frailty. Health Psychology Review, 2018, 12, 382-404.	4.4	32

#	Article	IF	CITATIONS
73	Predicting risk and outcomes for frail older adults: an umbrella review of frailty screening tools. JBI Database of Systematic Reviews and Implementation Reports, 2017, 15, 1154-1208.	1.7	163
74	A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women. Osteoporosis International, 2017, 28, 2445-2455.	1.3	11
75	SNPs in bone-related miRNAs are associated with the osteoporotic phenotype. Scientific Reports, 2017, 7, 516.	1.6	17
76	Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemporary Clinical Trials, 2017, 55, 56-62.	0.8	28
77	The Impact of Hormone Therapy on Health. , 2017, , 225-247.		0
78	Postmenopausal Osteoporosis. , 2017, , 125-140.		1
79	The Health Challenges at Menopause and Midlife: Sustainability, ICT Technology and Patient Empowerment. , 2017, , 333-342.		Ο
80	Frailty and multimorbidity: Two related yet different concepts. Maturitas, 2017, 95, 31-35.	1.0	107
81	Potential risks to offspring of intrauterine exposure to maternal age-related obstetric complications. Reproduction, Fertility and Development, 2017, 29, 1468.	0.1	5
82	Note of clarification: Potential risks to offspring of intrauterine exposure to maternal age-related obstetric complications. Reproduction, Fertility and Development, 2017, 29, 1653.	0.1	2
83	PREDICTIVE ACCURACY OF FRAILTY MEASURES: OVERVIEW OF REVIEWS. Innovation in Aging, 2017, 1, 380-381.	0.0	Ο
84	Sex Hormones and Healthy Psychological Aging in Women. Frontiers in Aging Neuroscience, 2017, 9, 439.	1.7	14
85	FOCUS: Frailty Management Optimisation through EIPAHA Commitments and Utilisation of Stakeholders' Input – an innovative European Project in elderly care*. Family Medicine and Primary Care Review, 2016, 3, 373-376.	0.1	17
86	Obstetric and offspring risks of women's morbid conditions linked to prior anticancer treatments. Reproductive Biology and Endocrinology, 2016, 14, 37.	1.4	5
87	Physical activity and healthy aging. Menopause, 2016, 23, 477-478.	0.8	6
88	Benefits of physical exercise in postmenopausal women. Maturitas, 2016, 93, 83-88.	1.0	61
89	Effectiveness of the interventions in preventing the progression of pre-frailty and frailty in older adults: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2016, 14, 4-19.	1.7	15
90	HDlive imaging of cystic uterine leiomyoma degeneration. Ultrasound in Obstetrics and Gynecology, 2016, 47, 655-656.	0.9	3

#	Article	IF	CITATIONS
91	Evaluation of the risk factors of asymptomatic vertebral fractures in postmenopausal women with osteopenia at the femoral neck. Maturitas, 2016, 87, 95-101.	1.0	2
92	The role of CD40 and CD40L in bone mineral density and in osteoporosis risk: A genetic and functional study. Bone, 2016, 83, 94-103.	1.4	19
93	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas, 2016, 83, 83-93.	1.0	39
94	Progestogens and risk of breast cancer: a link between bone and breast?. Gynecological Endocrinology, 2016, 32, 6-8.	0.7	8
95	The European Innovation Partnership on Active and Healthy Ageing Synergies: Protocol for a Prospective Observational Study to Measure the Impact of a Community-Based Program on Prevention and Mitigation of Frailty (ICP - PMF) in Community-Dwelling Older Adults. Translational Medicine @ UniSa. 2016. 15. 53-66.	0.8	9
96	Predicting risk and outcomes for frail older adults: a protocol for an umbrella review of available frailty screening tools. JBI Database of Systematic Reviews and Implementation Reports, 2015, 13, 14-24.	1.7	4
97	Deficiencies in reporting results of lesbians and gays after donor intrauterine insemination and assisted reproductive technology treatments: a review of the first emerging studies. Reproductive Biology and Endocrinology, 2015, 13, 52.	1.4	16
98	Infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases. Reproductive Biology and Endocrinology, 2015, 13, 31.	1.4	73
99	Mir-661: A key Factor in Embryo-Maternal dialog With Potential Clinical Application to Predict Implantation Outcome?. EBioMedicine, 2015, 2, 1312-1313.	2.7	3
100	Personalized health care for midlife and beyond. Maturitas, 2015, 82, 1-2.	1.0	3
101	Serum Circulating MicroRNAs as Biomarkers of Osteoporotic Fracture. Calcified Tissue International, 2015, 97, 495-505.	1.5	133
102	ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. European Journal of Endocrinology, 2015, 172, R53-R65.	1.9	82
103	Impact of estrogens on atherosclerosis and bone in the apolipoprotein E–deficient mouse model. Menopause, 2015, 22, 428-436.	0.8	12
104	Cognitive frailty, a new target for healthy ageing. Maturitas, 2015, 82, 139-140.	1.0	14
105	A decision dilemma: Cushing syndrome during pregnancy. Journal of Obstetrics and Gynaecology, 2015, 35, 93-94.	0.4	2
106	The impact of moderate wine consumption on health. Maturitas, 2015, 80, 3-13.	1.0	147
107	Models for preclinical studies in aging-related disorders: One is not for all. Translational Medicine @ UniSa, 2015, 13, 4-12.	0.8	15
108	Gene expression profile induced by ovariectomy in bone marrow of mice: A functional approach to identify new candidate genes associated to osteoporosis risk in women. Bone, 2014, 65, 33-41.	1.4	22

#	Article	IF	CITATIONS
109	Sequential use of antiresorptives in younger women. Osteoporosis International, 2014, 25, 1191-1192.	1.3	4
110	Assisted reproductive technology results: Why are liveâ€birth percentages so low?. Molecular Reproduction and Development, 2014, 81, 568-583.	1.0	27
111	Replication study of three functional polymorphisms associated with bone mineral density in a cohort of Spanish women. Journal of Bone and Mineral Metabolism, 2014, 32, 691-698.	1.3	6
112	Spanish Menopause Society position statement: Use of denosumab in postmenopausal women. Maturitas, 2014, 79, 117-121.	1.0	3
113	Changes in sex ratio from fertilization to birth in assisted-reproductive-treatment cycles. Reproductive Biology and Endocrinology, 2014, 12, 56.	1.4	46
114	Absence of long-term effects of reproduction on longevity in the mouse model. Reproductive Biology and Endocrinology, 2014, 12, 84.	1.4	13
115	Transient regional osteoporosis. Maturitas, 2014, 77, 324-329.	1.0	24
116	2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas, 2013, 76, 99-107.	1.0	25
117	The impact of coffee on health. Maturitas, 2013, 75, 7-21.	1.0	253
118	Nuclear receptor NR5A2 and bone: gene expression and association with bone mineral density. European Journal of Endocrinology, 2012, 166, 69-75.	1.9	5
119	The Adverse Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 797-807.	1.5	26
120	Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause, 2012, 19, 319-327.	0.8	7
121	Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture. Menopause, 2012, 19, 1193-1199.	0.8	8
122	Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric, 2012, 15, 455-459.	1.1	9
123	A multinational study of sleep disorders during female mid-life. Maturitas, 2012, 72, 359-366.	1.0	125
124	The impact of chocolate on cardiovascular health. Maturitas, 2011, 69, 312-321.	1.0	74
125	Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Molecular and Cellular Endocrinology, 2011, 335, 96-103.	1.6	80
126	Relationship of sclerostin and secreted frizzled protein polymorphisms with bone mineral density. Menopause, 2011, 18, 802-807.	0.8	19

#	Article	IF	CITATIONS
127	Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. European Journal of Endocrinology, 2011, 164, 123-131.	1.9	44
128	Estradiol selectively stimulates endothelial prostacyclin production through estrogen receptor-α. Journal of Molecular Endocrinology, 2010, 44, 237-246.	1.1	84
129	Isoflavones and cardiovascular disease. Maturitas, 2010, 67, 219-226.	1.0	75
130	Alleles and haplotypes of the estrogen receptor alpha gene are associated with an increased risk of spontaneous abortion. Fertility and Sterility, 2010, 93, 1809-1815.	0.5	23
131	Estradiol Stimulates Vasodilatory and Metabolic Pathways in Cultured Human Endothelial Cells. PLoS ONE, 2009, 4, e8242.	1.1	52
132	Long-Term Effects of Delayed Fatherhood in Mice on Postnatal Development and Behavioral Traits of Offspring1. Biology of Reproduction, 2009, 80, 337-342.	1.2	47
133	Delayed Fatherhood in Mice Decreases Reproductive Fitness and Longevity of Offspring1. Biology of Reproduction, 2009, 80, 343-349.	1.2	48
134	No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin production by human endothelial cells. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 144, 93-94.	0.5	5
135	Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertility and Sterility, 2009, 91, 1347-1350.	0.5	19
136	Comparative effects of 17β-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporosis International, 2008, 19, 793-800.	1.3	44
137	A C >T polymorphism located at position â^'1 of the Kozak sequence of CD40 gene is associated with low bone mass in Spanish postmenopausal women. Osteoporosis International, 2008, 19, 1147-1152.	1.3	14
138	The Asn19Lys Substitution in the Osteoclast Inhibitory Lectin (OCIL) Gene is Associated with a Reduction of Bone Mineral Density in Postmenopausal Women. Calcified Tissue International, 2008, 82, 348-353.	1.5	15
139	Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women. Gynecological Endocrinology, 2008, 24, 354-357.	0.7	3
140	Transdermal estradiol reduces F2α-isoprostane levels in postmenopausal women. Menopause, 2008, 15, 714-717.	0.8	6
141	Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovascular Research, 2007, 73, 66-72.	1.8	60
142	Selective estrogen receptor modulators and risk for coronary heart disease. Climacteric, 2007, 10, 97-111.	1.1	12
143	Raloxifeneâ \check{z} increases proliferation of human endothelial cells in association with increased gene expression of cyclins A and B1. Fertility and Sterility, 2007, 88, 326-332.	0.5	11
144	Beneficial effects of dithiothreitol on relative levels of glutathione S-transferase activity and thiols in oocytes, and cell number, DNA fragmentation and allocation at the blastocyst stage in the mouse. Molecular Reproduction and Development, 2007, 74, 860-869.	1.0	28

9

#	Article	IF	CITATIONS
145	The risk for cardiovascular disease in women: from estrogens to selective estrogen receptor modulators. Frontiers in Bioscience - Landmark, 2007, 12, 49.	3.0	7
146	Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women. Gynecological Endocrinology, 2006, 22, 179-184.	0.7	18
147	Delayed Motherhood Decreases Life Expectancy of Mouse Offspring1. Biology of Reproduction, 2005, 72, 1336-1343.	1.2	44
148	Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2. Fertility and Sterility, 2005, 83, 1822-1829.	0.5	20
149	Effects of Phytoestrogens Genistein and Daidzein on Prostacyclin Production by Human Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 722-728.	1.3	50
150	Association of female aging with decreased parthenogenetic activation, raised MPF, and MAPKs activities and reduced levels of glutathione S-transferases activity and thiols in mouse oocytes. Molecular Reproduction and Development, 2004, 69, 402-410.	1.0	43
151	Bone Turnover Markers and PTH Levels in Surgical Versus Natural Menopause. Calcified Tissue International, 2004, 74, 143-149.	1.5	12
152	Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause, 2004, 11, 430-437.	0.8	14
153	The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women. Archives of Gynecology and Obstetrics, 2003, 268, 317-322.	0.8	4
154	Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 705-710.	1.3	8
155	Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 109, 234-235.	0.5	7
156	Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas, 2003, 45, 67-74.	1.0	21
157	The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen. Menopause, 2003, 10, 154-159.	0.8	8
158	Long-term effects of delayed motherhood in mice on postnatal development and behavioural traits of offspring. Human Reproduction, 2003, 18, 1580-1587.	0.4	27
159	Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 705-710.	1.3	20
160	Postovulatory Aging of Oocytes Decreases Reproductive Fitness and Longevity of Offspring1. Biology of Reproduction, 2002, 66, 495-499.	1.2	72
161	Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH) Tj ETQq	1 1 0.7843 0.8	314.rgBT /Ov
162	Estradiol reduces F _{2α} -isoprostane production in cultured human endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2644-H2649.	1.5	14

10

#	Article	IF	CITATIONS
163	Oral antioxidants counteract the negative effects of female aging on oocyte quantity and quality in the mouse. Molecular Reproduction and Development, 2002, 61, 385-397.	1.0	97
164	Stage of the estrous cycle at the time of pregnant mare's serum gonadotropin injection affects the quality of ovulated oocytes in the mouse. Molecular Reproduction and Development, 2002, 61, 398-405.	1.0	25
165	Stage of the estrous cycle at the time of pregnant mare's serum gonadotropin injection affects pre-implantation embryo development in vitro in the mouse. Molecular Reproduction and Development, 2002, 62, 312-319.	1.0	14
166	Predictive variables of in vitro fertilization and pre-implantation embryo development in the mouse. Molecular Reproduction and Development, 2002, 63, 38-46.	1.0	3
167	Metabolismo lipÃdico y aterogénesis femenina: acción de hormonas, SERM y fitoestrógenos. Progresos En Obstetricia Y Ginecologia, 2001, 44, 99-107.	0.0	0
168	The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause. Maturitas, 2001, 40, 173-181.	1.0	10
169	The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas, 2001, 40, 17-38.	1.0	39
170	Delayed motherhood increases the probability of sons to be infertile. Journal of Assisted Reproduction and Genetics, 2001, 18, 650-654.	1.2	10
171	The effects on offspring of premature parturition. Human Reproduction Update, 2001, 7, 487-494.	5.2	8
172	Cellular and Morphological Traits of Oocytes Retrieved from Aging Mice after Exogenous Ovarian Stimulation1. Biology of Reproduction, 2001, 65, 141-150.	1.2	102
173	The endometrial effects of SERMs. Human Reproduction Update, 2000, 6, 244-254.	5.2	40
174	Modulation of the oestrogen receptor: a process with distinct susceptible steps. Human Reproduction Update, 2000, 6, 207-211.	5.2	23
175	Pure anti-oestrogens. Human Reproduction Update, 2000, 6, 237-243.	5.2	31
176	Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease. Thrombosis and Haemostasis, 1999, 81, 516-521.	1.8	72
177	Lipoprotein(a) Levels and Isoforms and Fibrinolytic Activity in Postmenopause – Influence of Hormone Replacement Therapy. Thrombosis and Haemostasis, 1999, 81, 104-110.	1.8	19
178	Long-Term Effects of Postovulatory Aging of Mouse Oocytes on Offspring: A Two-Generational Study1. Biology of Reproduction, 1999, 61, 1347-1355.	1.2	102
179	Effect of intracellular Ca2+ chelation with the acetoxymethyl ester-derived form of bis(o-aminophenoxy)ethane-N,N,N,N',N'-tetraacetic acid on meiotic division and chromosomal segregation in mouse oocytes. Journal of Assisted Reproduction and Genetics, 1999, 16, 276-282.	1.2	4
180	Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapyâ~†. Fertility and Sterility, 1999, 71, 129-136.	0.5	14

#	Article	IF	CITATIONS
181	Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone–stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility, 1999, 71, 261-267.	0.5	43
182	Effects of maternal ageing and dietary antioxidant supplementation on ovulation, fertilisation and embryo development in vitro in the mouse. Reproduction, Nutrition, Development, 1998, 38, 499-508.	1.9	23
183	Sex selection may be inadvertently performed in in-vitro fertilization—embryo transfer programmes. Human Reproduction, 1995, 10, 2992-2998.	0.4	58
184	Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood. Human Reproduction, 1995, 10, 63-67.	0.4	10
185	The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. American Journal of Obstetrics and Gynecology, 1995, 173, 1849-1854.	0.7	72
186	Influence of the ovary on parameters of LH secretion during the recovery from buserelin-induced desensitization. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1994, 55, 187-192.	0.5	1
187	Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas, 1994, 20, 91-99.	1.0	82
188	Fulminant subarachnoidal hemorrhage and coma subsequent to sudden-presenting hypertension. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 47, 80-82.	0.5	6
189	Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins. Maturitas, 1991, 13, 35-42.	1.0	22
190	Demonstration of P29, an oestrogen receptor-associated tumor marker, in human term placenta. Placenta, 1991, 12, 153-160.	0.7	3
191	Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause**Supported by grant 87/1503 from the Fondo de Investigaciones Sanitarias, Madrid, Spain Fertility and Sterility, 1990, 54, 1058-1064.	0.5	31
192	p29 Protein in Breast Cancer: Relation between Estrogen and Progesterone Receptors. Tumori, 1989, 75, 113-116.	0.6	2
193	Oestrogen and progesterone receptors in human term placenta. Measurement by binding assays and immunological methods. Placenta, 1989, 10, 579-588.	0.7	17
194	Immunoradiometric Studies with a Monoclonal Antibody against an Estrogen-Receptor-Related Protein in Human Breast Cancer. Gynecologic and Obstetric Investigation, 1988, 26, 166-170.	0.7	4
195	Cardiovascular Disease and SERMs. , 0, , 207-238.		0